The CHI SQUARE Trial

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
The CHI SQUARE Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of The CHI SQUARE Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on The CHI SQUARE Trial
CDC on The CHI SQUARE Trial
The CHI SQUARE Trial in the news
Blogs on The CHI SQUARE Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for The CHI SQUARE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To determine the safety and efficacy of CER-001 on atherosclerotic plaque progression and regression in patients with acute coronary syndromes.

Methods

CHI-SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? This is a phase II, multi-centered, double-blinded, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndromes. 504 patients were grouped into: placebo, low dose, mid dose, and high dose of CER-001 groups to receive a total of 6 infusions in 5 weeks. The total coronary plaque volume is measured with intravascular ultrasound (IVUS).

Results

Pending

Conclusion

Pending